Eagle Pharma expands licensing agreement for BENDEKA with Teva

Eagle Pharma扩大与Teva签订现有BENDEKA许可协议,特许权使用费增加到30%

2019-04-15 21:30:29 seekingalpha

本文共266个字,阅读需1分钟

Eagle Pharmaceuticals has expanded its existing BENDEKA licensing agreement with Teva Pharmaceuticals . Under the terms of the revised licensing agreement, beginning on October 1, Eagle’s royalty payment will increase from 25% to 30% of BENDEKA net U.S. sales. The royalty rate will increase by one percentage point on each anniversary, until it reaches 32%, and it will remain at 32% thereafter. The revised agreement also extends the U.S. BENDEKA royalty term until it is no longer sold in the U.S. The previous U.S. royalty term was set to expire in 2025. The extended term recognizes the strength of the bendamustine patents with expiries through 2033. As part of the agreement restructuring, Eagle has also agreed to assume a portion of the BENDEKA-related patent litigation expenses.
鹰药业扩大了与梯瓦(Teva)药业现有的 BENDEKA 许可协议。 根据修订后的许可协议条款,从10月1日开始, Eagle 的特许权使用费将从25%增加到 BENDEKA 美国净销售额的30%。版税将在每一周年增加一个百分点,直到达到32%,之后将保持在32%。 修订后的协议还延长了美国 BENDEKA 的特许权使用费期限,直至其不再在美国销售。之前的美国特许权使用费期限定于2025年到期。 延长的期限确认了在2033年到期的苯达莫司汀专利的强度。 作为协议重组的一部分,鹰还同意承担部分 BENDEKA 相关专利诉讼费用。

以上中文文本为机器翻译,存在不同程度偏差和错误,请理解并参考英文原文阅读。

阅读原文